Quantcast

Latest Fusion protein Stories

2014-04-03 08:22:27

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gw6znv/the_engineered ) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective...

2014-03-26 23:24:54

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins Geneva, Switzerland (PRWEB) March 26, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™...

2014-02-27 23:27:06

Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically Improve Biologic Protein Expression in Mammalian Cell Lines Geneva, Switzerland (PRWEB) February 27, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the SURE CHO-Mplus™ Libraries to...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2013-10-29 23:22:36

Reportbuyer.com just published a new market research report: World Biological Drugs Market 2013-2023. London (PRWEB) October 29, 2013 Report Details Biologics - discover and assess products with highest revenue potential Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects. In that...

2013-10-24 23:25:16

MarketResearchReports.Biz announces addition of new report “Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-and-cells-emerging-opportunities-for-the-biopharmaceutical-industry. Albany, NY (PRWEB) October 24, 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities...

2013-06-05 13:16:02

A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield. Using the bacterium E. coli, researchers from the University's Faculty of Engineering showed it was possible to vastly increase the efficiency of the cells producing specifically modified proteins, as well as improve its performance and stability. The modification is present in over two-thirds of human therapeutic drugs on the market and involves the...

2013-05-29 23:14:13

Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus Library Can Improve Product Yield in Mammalian Cell Lines Geneva, Switzerland (PRWEB) May 29, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the newly launched SURE CHO-Mplus Library to address a broad range of...

2013-04-17 23:04:13

Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression. Geneva, Switzerland (PRWEB) April 17, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion including...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related